Home/Filings/4/0000950170-24-078790
4//SEC Filing

Jacobs Bruce N. 4

Accession 0000950170-24-078790

CIK 0001815442other

Filed

Jun 27, 8:00 PM ET

Accepted

Jun 28, 8:30 AM ET

Size

7.0 KB

Accession

0000950170-24-078790

Insider Transaction Report

Form 4
Period: 2024-06-27
Jacobs Bruce N.
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2024-06-27$2.08/sh+25,000$52,000168,554 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-06-2725,000104,899 total
    Exercise: $2.08Exp: 2029-08-28Common Stock (25,000 underlying)
Footnotes (2)
  • [F1]This number includes 1,203 shares acquired under the Registrant's employee stock purchase plan on June 1, 2024.
  • [F2]Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.

Documents

1 file

Issuer

Kymera Therapeutics, Inc.

CIK 0001815442

Entity typeother

Related Parties

1
  • filerCIK 0001821074

Filing Metadata

Form type
4
Filed
Jun 27, 8:00 PM ET
Accepted
Jun 28, 8:30 AM ET
Size
7.0 KB